IP Verse

Bilayer Tablet Formulations - EP2498758

The patent EP2498758 was granted to Astrazeneca on Jul 25, 2018. The application was originally filed on Nov 12, 2010 under application number EP10782113A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2498758

ASTRAZENECA
Application Number
EP10782113A
Filing Date
Nov 12, 2010
Status
Granted And Under Opposition
Jun 22, 2018
Grant Date
Jul 25, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOEFER & PARTNER PATENTANWALTE MBBApr 25, 2019-WITHDRAWN

Patent Citations (102) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS19990391053-
DESCRIPTIONUS20040899641-
DESCRIPTIONEP0142146
DESCRIPTIONEP0221025
DESCRIPTIONEP2009010
DESCRIPTIONFR2596393
DESCRIPTIONGB2205837
DESCRIPTIONUS100000
DESCRIPTIONUS2007197623
DESCRIPTIONUS2009030198
DESCRIPTIONUS3674836
DESCRIPTIONUS3983140
DESCRIPTIONUS4027009
DESCRIPTIONUS4231938
DESCRIPTIONUS4346227
DESCRIPTIONUS4448784
DESCRIPTIONUS4450171
DESCRIPTIONUS4499289
DESCRIPTIONUS4613610
DESCRIPTIONUS4647576
DESCRIPTIONUS4681893
DESCRIPTIONUS4686237
DESCRIPTIONUS4759923
DESCRIPTIONUS4871721
DESCRIPTIONUS4924024
DESCRIPTIONUS5006530
DESCRIPTIONUS5011930
DESCRIPTIONUS5177080
DESCRIPTIONUS5260440
DESCRIPTIONUS5273995
DESCRIPTIONUS5354772
DESCRIPTIONUS5385929
DESCRIPTIONUS5488064
DESCRIPTIONUS5491134
DESCRIPTIONUS5506219
DESCRIPTIONUS5541204
DESCRIPTIONUS5594016
DESCRIPTIONUS5595872
DESCRIPTIONUS5612359
DESCRIPTIONUS5614492
DESCRIPTIONUS5686104
DESCRIPTIONUS5691322
DESCRIPTIONUS5712279
DESCRIPTIONUS5712396
DESCRIPTIONUS5739135
DESCRIPTIONUS5753675
DESCRIPTIONUS5760246
DESCRIPTIONUS5770615
DESCRIPTIONUS5776983
DESCRIPTIONUS5827875
DESCRIPTIONUS5885983
DESCRIPTIONUS5962440
DESCRIPTIONUS6043265
DESCRIPTIONUS6395767
DESCRIPTIONUS6414002
DESCRIPTIONUS6515117
DESCRIPTIONUS6548529
DESCRIPTIONUS6653314
DESCRIPTIONUS7288528
DESCRIPTIONUS7589193
DESCRIPTIONWO0001389
DESCRIPTIONWO0039077
DESCRIPTIONWO0121602
DESCRIPTIONWO03033671
DESCRIPTIONWO03099836
DESCRIPTIONWO2005117841
DESCRIPTIONWO2007007628
DESCRIPTIONWO2008002824
DESCRIPTIONWO2008116179
DESCRIPTIONWO2009003596
DESCRIPTIONWO8603488
DESCRIPTIONWO8607054
DESCRIPTIONWO9638144
DESCRIPTIONWO9712613
DESCRIPTIONWO9712615
DESCRIPTIONWO9721993
DESCRIPTIONWO9900353
DESCRIPTIONWO9938501
DESCRIPTIONWO9946272
DESCRIPTIONWO9961431
DESCRIPTIONWO9967278
DESCRIPTIONWO9967279
INTERNATIONAL-SEARCH-REPORTWO2005117841
INTERNATIONAL-SEARCH-REPORTWO2008113000
INTERNATIONAL-SEARCH-REPORTWO2008116179
INTERNATIONAL-SEARCH-REPORTWO2010045656
OPPOSITIONUS2005266080
OPPOSITIONUS2006057202
OPPOSITIONUS2008234366
OPPOSITIONUS5955106
OPPOSITIONWO2005117841
OPPOSITIONWO2007078726
OPPOSITIONWO2008113000
OPPOSITIONWO2008116179
OPPOSITIONWO2009011451
OPPOSITIONWO2009099734
OPPOSITIONWO2009111200
OPPOSITIONWO2009121945
OPPOSITIONWO2009143021
OPPOSITIONWO2010045656
OPPOSITIONWO2010138535
OPPOSITIONWO2011039337

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- ANONYMOUS, "View of NCT01002807 on 2009_10_26", ClinicalTrials.gov NCT01002807, (20091026), XP055585789-
OPPOSITION- J. CALADO, "Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus", IDrugs: The Investigational Drugs Jou, (20091200), vol. 12, no. 12, pages 785 - 798, XP009136677-
OPPOSITION- Levien T L et al, "New drugs in development for the treatment of diabetes", Diabetes Spectrum, (20090000), vol. 22, no. 2, pages 92 - 106, XP009123031-
OPPOSITION- M. PFISTER et al., "Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus", Clinical Pharmacology & Therapeutics, (20090500), vol. 85, no. 5, pages 513 - 519, XP009146835-
OPPOSITION- U. MANDAL et al., "Formulation and In Vitro Studies of a Fixed-DoseCombination of a Bilayer Matrix Tablet ContainingMetformin HCl as Sustained Release and Glipizideas Immediate Release", Drug Development and Industrial Pharmacy, (20080000), vol. 34, no. 3, pages 305 - 313, XP055585729
OPPOSITION- List J F et al, "Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes", Diabetes Care, (20090400), vol. 32, no. 4, pages 650 - 657, XP055012106

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents